Goal
Provide antimicrobial, antifungal, antiviral, and broader therapeutic activity against pathogens and disease conditions.
Problem
Pathogenic microorganisms (bacteria, fungi, viruses, parasites) and related diseases; need for effective, non-staining, light-stable disinfectants and pharmaceuticals.
Concept Summary
The invention discloses electron-active multivalent metal-oxide compounds-particularly tetra-copper tetroxide (Cu(I)_2Cu(III)_2O_4)-as pharmaceutical or disinfectant agents. The compounds contain at least two polyvalent cations with differing oxidation states, giving them a redox potential (EMF >= +0.1 V) that enables pathogen killing. The patent describes preparation methods (copper(I) oxide + caustic base + persulfate, heated) and therapeutic use (topical, parenteral, transdermal) at concentrations from 1 ppm to 500 000 ppm, optionally with oxidizing agents to enhance efficacy.
Principles
- Electron-transfer redox activity of multivalent metal oxides
- Oxidative activation by persulfate (peroxy acid salt)
- Polyvalent cation synergy (different oxidation states)
- Dose-dependent antimicrobial efficacy
Scientific Domains
Materials
- Copper(I) oxide (Cu_2O)
- Copper(III) oxide (Cu_2O_3) - generated in situ
- Persulfate (e.g., sodium persulfate)
- Hydroxide salts (e.g., NaOH, KOH)
- Water
Mechanisms of Action
- Redox-mediated disruption of microbial cell membranes
- Generation of reactive oxygen species via persulfate activation
- Metal-ion toxicity to pathogens
Applications
- Topical antimicrobial creams
- Water disinfection
- Pharmaceutical treatment of infections
- Surface sanitization
Claimed Performance
Antimicrobial efficacy of >=20 % (up to >=80 %) at ~100 ppm after 10 min contact; pathogen killing demonstrated at concentrations as low as 0.3 ppm for related silver tetroxide compositions.
Experimental Evidence
The patent text cites in-vitro studies for tetrasilver tetroxide (0.3 ppm, 10 min) but provides no quantitative data for tetracopper tetroxide; efficacy is asserted rather than experimentally demonstrated.
Limitations
- No published in-vivo or clinical data for TCTO
- Potential copper toxicity and hepatomegaly at high doses
- Requirement for oxidizing agent to achieve full efficacy
- Stability and formulation challenges
Red Flags
- Efficacy claims lack peer-reviewed experimental data
- Potential for liver enlargement (hepatomegaly) noted in related silver studies
- Broad therapeutic claims without clinical validation
